Ultragenyx Pharmaceutical Incis A Biopharmaceutical Company Based In Novatocaliforniafocused On Developing Innovative Treatments For Rare And Ultra Rare Genetic Diseasesfounded In 2010 By Emil Dkakkism D Ph D The Company Is Publicly Traded On Nasdaq Under The Ticker Symbol Rareultragenyx Is Dedicated To Addressing Unmet Medical Needs In The Rare Disease Community Through Meaningful Engagement With Patients And Their Caregivers The Company Develops Therapies Primarily For Metabolic Diseasesneurological Disordersand Other Rare Genetic Conditionsnotable Products Include Crysvita For X Linked Hypophosphatemiadojolvi For Long Chain Fatty Acid Oxidation Disordersand Mepsevii For Mucopolysaccharidosis Viiultragenyx Has A Robust Pipeline With Multiple Programs In Various Stages Of Developmentreflecting Its Commitment To Advancing Treatments Through Research And Development With A Total Of 652 Employees As Of December 2023Ultragenyx Operates Commercially In The United States And Collaborates Globally On Research Initiativesthe Company Also Emphasizes Corporate Sustainability And Aims To Positively Impact Patients While Considering Broader Societal And Environmental Responsibilities
No conferences found for this company.
| Company Name | Genetx Biotherapeutics Llc |
| Country |
United States
|
| Address | N/A |
| Telephone | N/A |
| N/A |
